Analysts Set Vaxcyte, Inc. (NASDAQ:PCVX) PT at $136.50

Shares of Vaxcyte, Inc. (NASDAQ:PCVX) have been assigned an average recommendation of “Buy” from the ten analysts that are covering the firm, Marketbeat reports. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $136.50.

PCVX has been the subject of several research analyst reports. The Goldman Sachs Group decreased their price target on shares of Vaxcyte from $138.00 to $100.00 and set a “buy” rating for the company in a research note on Tuesday, April 1st. Needham & Company LLC reissued a “buy” rating and set a $90.00 target price on shares of Vaxcyte in a research report on Tuesday, April 8th. Evercore ISI raised shares of Vaxcyte to a “strong-buy” rating in a research report on Monday, March 31st. Cantor Fitzgerald assumed coverage on shares of Vaxcyte in a research report on Tuesday, April 22nd. They set an “overweight” rating for the company. Finally, Bank of America decreased their target price on shares of Vaxcyte from $157.00 to $137.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st.

Vaxcyte Price Performance

Shares of Vaxcyte stock opened at $30.90 on Friday. Vaxcyte has a fifty-two week low of $27.66 and a fifty-two week high of $121.06. The firm has a market capitalization of $3.99 billion, a P/E ratio of -6.72 and a beta of 1.27. The company’s 50 day moving average price is $43.32 and its two-hundred day moving average price is $72.46.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). During the same period in the prior year, the business posted ($0.85) EPS. On average, analysts expect that Vaxcyte will post -4.21 earnings per share for the current year.

Insiders Place Their Bets

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $73.27, for a total value of $586,160.00. Following the transaction, the chief operating officer now directly owns 154,931 shares in the company, valued at $11,351,794.37. The trade was a 4.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 3.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Whipplewood Advisors LLC purchased a new position in Vaxcyte in the fourth quarter valued at about $28,000. Smartleaf Asset Management LLC boosted its stake in Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock valued at $33,000 after acquiring an additional 260 shares during the last quarter. National Bank of Canada FI purchased a new position in Vaxcyte in the fourth quarter valued at about $41,000. Blue Trust Inc. boosted its stake in Vaxcyte by 100.0% in the fourth quarter. Blue Trust Inc. now owns 742 shares of the company’s stock valued at $61,000 after acquiring an additional 371 shares during the last quarter. Finally, Assetmark Inc. lifted its stake in shares of Vaxcyte by 77,500.0% during the 4th quarter. Assetmark Inc. now owns 776 shares of the company’s stock valued at $64,000 after buying an additional 775 shares in the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.